The RAB39B antibody is a crucial tool for studying the RAB39B protein, a member of the RAB GTPase family involved in regulating intracellular vesicle trafficking, membrane dynamics, and autophagy. RAB39B localizes to the Golgi apparatus and endosomal compartments, where it plays a role in cargo transport, synaptic vesicle formation, and lysosomal function. Research has linked RAB39B mutations to neurodevelopmental and neurodegenerative disorders, particularly X-linked Parkinson’s disease (PD) and intellectual disability. Loss-of-function mutations disrupt α-synuclein homeostasis, dopamine signaling, and synaptic plasticity, contributing to PD-like pathology. The antibody enables detection of RAB39B expression levels, subcellular localization, and interactions in experimental models (e.g., neurons, patient-derived cells, or animal models). It is widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to explore RAB39B’s role in disease mechanisms or cellular pathways. Commercially available RAB39B antibodies are typically validated for specificity via knockout controls. Recent studies also utilize these antibodies to investigate RAB39B’s interplay with other PD-associated proteins (e.g., LRRK2. PINK1) and its potential as a therapeutic target. Understanding RAB39B dysfunction through antibody-based assays provides insights into neurodegeneration and autophagy-related pathways, advancing both basic research and translational applications.